RB1 and melanoma: CDK4/6 inhibitors represent promising candidates for cancer therapy (reviewed in [53–55]), since alterations in the cyclin D-CDK4/6-p16INK4A-Rb pathway occur frequently in various type of tumors, including the majority of melanomas, and promote continued growth.